Skip to main content

Table 1 Variables collected in the COVID-VIT-D trial included in this report

From: A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D—a randomised multicentre international clinical trial

Demographic and comorbidities

 Date of birth

Diabetes (yes/no)

 Gender (male/female)

Cardiovascular disease (yes/no)

 Height (cm)

Hypertension (yes/no)

 Weight (kg)

Asthma (yes/no)

COPD (yes/no)

Hospitalisation (clinical and evolutive data)

 Hospital admission date

Death date

 Hospital discharge date

 

Biochemical and imaging parameters at admission and discharge

 Calcidiol (ng/mL)

Interleukin-6 (pg/mL)

 CRP (mg/dL)

Ferritin (ng/mL)

 Albumin (g/L)

Calcium (mg/dL)

 Haemoglobin (g/dL)

Phosphate (mgl/dL)

 LDH (U/L)

X-Ray/CAT (positive/ doubtful/negative)

 Leucocytes (No./μL)

 

Types of drugs received during the hospitalisation

 Cholecalciferol (yes/no)

Enoxaparin (yes/no)

 Azithromycin (yes/no)

Methylprednisolone (yes/no)

 Ceftriaxone (yes/no)

Dexamethasone (yes/no)

  1. COPD Chronic obstructive pulmonary, CRP C-reactive protein, CAT Computed axial tomography